177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study

Clinical trial NCT04786847 · COMPLETED

Trial details

NCT number: NCT04786847
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Metastatic Prostate Cancer

Start date: 2022-01-30
Primary completion: 2023-09-30
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.